As the saying goes, it’s an ill wind that blows nobody any good, and the pharma industry appears to be at least a partial beneficiary of the current coronavirus pandemic. No longer do the newspaper headlines focus on excessive drug prices: all the attention...
The changing of the guard: New CEOs move in
Recent months have seen a slew of management changes at major generics companies. Some of this has been driven by shareholder dissatisfaction with poor performance (Teva being the obvious example here), but there have also been generational and other shifts that offer interesting pointers...